Ironwood Pharmaceuticals (IRWD) Cash & Equivalents (2009 - 2026)

Ironwood Pharmaceuticals has disclosed Cash & Equivalents across 18 years of filings, most recently posting $220.5 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $220.5 million, up 103.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $220.5 million (up 103.23% YoY), and the FY2025 annual result was $215.5 million, up 143.29% from the prior year.
• Cash & Equivalents came in at $220.5 million for Q1 2026 at Ironwood Pharmaceuticals, up from $215.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $740.3 million in Q1 2023 to a low of $88.2 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $140.4 million (2025), against an average of $272.2 million.
• Across the five-year window, Cash & Equivalents plunged 85.96% in 2023 and jumped 143.29% in 2025, its largest moves.
• Ironwood Pharmaceuticals' Cash & Equivalents stood at $656.2 million in 2022, then slumped by 85.96% to $92.2 million in 2023, then retreated by 3.9% to $88.6 million in 2024, then surged by 143.29% to $215.5 million in 2025, then gained by 2.33% to $220.5 million in 2026.
• The last three Cash & Equivalents figures came in at $220.5 million (Q1 2026), $215.5 million (Q4 2025), and $140.4 million (Q3 2025), per Business Quant data.